a16z Podcast: All About Synthetic Biology

Episode Summary

Executive Summary: The episode traces synthetic biology from its origins in systems biology and engineering thinking to its modern role in therapeutics, diagnostics, and education. Jim Collins explains how synthetic biologists moved from reverse-engineering gene networks to intentionally designing genetic circuits like the toggle switch, why engineering and biology differ culturally, and how the field has matured past hype into more practical product and platform companies—while also pointing to future frontiers in machine learning, climate, and classroom bio-kits.

Main Topics: Origins of synthetic biology (Priority: 5/5): The field emerged in the late 1990s as genomics produced parts lists but not network-level understanding, drawing engineers and physicists into biology to help model and reconstruct complex cellular systems. Engineering gene circuits (Priority: 5/5): Collins recounts the creation of the first genetic toggle switch, a bistable circuit inspired by electrical engineering and built from mutually inhibitory genes to create on/off memory in cells. Biology vs. engineering culture (Priority: 5/5): The conversation explores the tension between scientific curiosity and engineering purpose, including differing views on mechanism, controls, trial-and-error, and the legitimacy of design-led biology. Bacteria as programmable living systems (Priority: 5/5): E. coli became the workhorse chassis for early SynBio, leading to biosensors, diagnostics, and therapeutics such as engineered bacteria for cholera and later clinical applications at Synlogic. Design principles, directed evolution, and machine learning (Priority: 4/5): Collins argues that the field still lacks robust design principles, relying on iterative engineering; he sees directed evolution and machine learning as key complements for future optimization. Business models: platform vs product (Priority: 4/5): Synthetic biology companies must choose between building broad enabling platforms or focused products, with success depending on timing, partnerships, and disciplined go-to-market decisions. Education and future applications (Priority: 4/5): BioBits kits bring cell-free synthetic biology into classrooms, and Collins sees major opportunities in climate, carbon capture, plant resilience, and coral reef protection.

Key Arguments: The genome era created extensive parts lists, but not the network understanding needed to explain living systems; synthetic biology arose to fill that gap with engineering methods. Reverse engineering biology requires perturbation and modeling, much like diagnosing wiring in a house or circuit board. The first gene toggle switch proved that designed biological circuits could work, even after experts said it was impossible. Biologists and engineers optimize for different ends: scientists seek understanding, while engineers seek functional outcomes; both approaches are valuable. E. coli was a practical initial chassis because it was well-studied and had enough characterized parts to support early design-build-test cycles. The field initially suffered from hype, especially around biofuels, because lab-scale successes did not translate economically to industrial scale. Synthetic biology now looks more useful and grounded, especially in biomedicine, diagnostics, therapeutics, and enabling technologies like CRISPR. Companies must decide whether they are platform businesses or product businesses; trying to be both creates strategic confusion. Directed evolution is a powerful complement to rational design, though engineers may resist it because it feels like cheating. Machine learning will become increasingly important if the field can generate enough diverse, well-characterized data. Early education matters: giving students hands-on synthetic biology tools can reshape how they think about designing solutions to biological problems. Future growth areas include environmental engineering, carbon capture, heat-tolerant coral ecosystems, and programmable plants.

Data Points: Time spent designing the toggle switch: About 9 months - Collins says the first genetic toggle switch took roughly nine months of design and modeling before a functioning system was built. Publicly available datasets at the time: 7 datasets - He notes that when the effort began, there were only seven publicly available datasets, making large-scale network reverse engineering seem unrealistic. Gene annotation gap in E. coli: 30% to 40% - Collins says a high fraction of E. coli genes remained functionally unannotated despite it being a well-studied organism. Partnering calls to get funding: Once a month for over 6 months - He describes repeatedly contacting an ONR program officer to secure support for building the gene circuit in the lab. Synthetic biology field delay: About 2.5 years of little output - After early landmark papers, he says there was a pause because the field didn’t yet really exist and few experiments were underway. Gas price threshold: North of $4 per gallon - He cites rising gas prices around 2004 as one driver of the bioenergy wave. Scale mismatch for biofuels: $1 worth produced at $8 cost - He explains why many early bioenergy startups failed economically at industrial scale. Company age: 50 years old - He jokes about his age when introducing the BioBits classroom kit discussion by referencing a childhood chemistry set.

Pivotal Quotes: "biology by design" — Jim Collins: He uses this phrase to define synthetic biology as intentional construction of biological systems rather than passive study. "The scientist really wants to understand, and making it work is proof of understanding, but understanding is the real ends, and making it work is the means, whereas for the engineer, making it work is the ends, and understanding is the means." — Jim Collins: A central framing of the cultural difference between scientific and engineering mindsets. "The field got grounded and really began building out more broadly tools, constructs, platforms, and turned toward biomedicine." — Jim Collins: His explanation of how synthetic biology moved beyond bioenergy hype into more practical and clinically relevant work.

Implications: Synthetic biology is shifting from promise to practice. Expect more engineered therapeutics, diagnostics, climate solutions, and classroom tools, but success will depend on better design principles, data, and disciplined business models.